WO2014045300A2 - "topical drug delivery system" - Google Patents

"topical drug delivery system" Download PDF

Info

Publication number
WO2014045300A2
WO2014045300A2 PCT/IN2013/000530 IN2013000530W WO2014045300A2 WO 2014045300 A2 WO2014045300 A2 WO 2014045300A2 IN 2013000530 W IN2013000530 W IN 2013000530W WO 2014045300 A2 WO2014045300 A2 WO 2014045300A2
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
drug delivery
topical drug
casing
medication
Prior art date
Application number
PCT/IN2013/000530
Other languages
French (fr)
Other versions
WO2014045300A3 (en
Inventor
Rajeev Raut
Original Assignee
Fdc Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fdc Limited filed Critical Fdc Limited
Publication of WO2014045300A2 publication Critical patent/WO2014045300A2/en
Publication of WO2014045300A3 publication Critical patent/WO2014045300A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0026Ophthalmic product dispenser attachments to facilitate positioning near the eye
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body
    • A61M35/003Portable hand-held applicators having means for dispensing or spreading integral media

Definitions

  • the present invention relates to a novel topical drug delivery system useful in treatment of infections and inflammations on body surfaces of humans and animals.
  • Infections and inflammations are very common in humans and animals. Infection is an invasion of viruses, bacteria, parasites and fungi in the body; whereas inflammation is the first response of body's immune system to infection, irritation or injury caused to the body surface. Infections and inflammations can occur on any part of the body surfaces such as skin, eyes, ears, nose and mouth.
  • Skin forms a major part of the body surface which is exposed, and hence is most likely to get infected. Skin infections are often the result of breaks in the integrity of the skin, which enables pathogens such as virus, bacteria, fungi and yeast to inoculate into the dermis to cause infection. Skin infections can also result from a cut, scrape, insect bite, burn or any other skin wound. Skin infections caused by bacteria include acne/pimples, erythrasma, impetigo, ecthyma, folliculitis, erysipelas and cellulites. Skin infection can result in skin inflammation, which is known as infective dermatitis. Moreover infections to ears, nose and mouth that can lead to inflammation are also a growing cause of concern for humans and animals.
  • Topical treatment of such infections and inflammations generally involve mild cleansing of the infected site, and gentle application of required medication over the infected skin site.
  • topical treatments there is a possibility of contamination through hands used for applying the medication to infected site, while the hands barely reaching the site of application in certain cases, due to which hygienic and uniform application of medications to the treatment areas on body surfaces, is not achieved, and the period of treatment is further delayed. Therefore, treatments of infections and inflammations are required to achieve uniform application of medication over the treatment area, while maintaining proper hygiene of hands which is usually obtained using disposable hand gloves.
  • viruses Many of the viruses, bacteria, parasites and fungi, which invade the human body and cause infections, are also capable of attacking the surface or interior of the eye, leading to eye infections and inflammations.
  • Eyelid is an important part of the eye, and eyelid inflammations have become a cause of major concern for most of the people suffering from eye diseases.
  • Blepharitis, meibomitis, blepharoconjunctivitis, ocular rosacea, styes and chalazion are some of the eye diseases causing eyelid inflammation, which results into eye irritation, eye itching, eye discharge, excessive tear production and eye discomfort.
  • Blepharitis is an inflammation of the eyelids, particularly at the margins of the eyelids, caused due to collection of oil, dandruff, mucin, bacteria, pollutants or eye makeup on and around the eyelids and eyelashes.
  • dandruff-like scales and particles are formed along the eyelid margins and base of eyelashes.
  • Blepharitis is mainly classified into i) anterior blepharitis that affects the outer margin of the eyelids where the eyelashes are located; and ii) posterior blepharitis that affects the inner rim of eyelids where the meibomian glands are situated.
  • Blepharitis can occur as staphylococcal blepharitis, seborrhoeic blepharitis, allergic blepharitis, ulcerative blepharitis and/or blepharitis caused due to skin cancers or systemic medical conditions. Severe blepharitis can be associated with conjunctivitis, known as blepharoconjunctivitis.
  • Meibomitis is an inflammation of the meibomian glands located in the eyelids, and is very closely related to blepharitis. Meibomitis is also known as meibomian gland dysfunction (MGD), wherein the meibomian gland openings on the eyelid margins become blocked with inspicated meibomian secretions, and the oil secreted by the meibomian glands is thicker and has a milky appearance, rather than a clear oil that prevents tear evaporation, thus leading to eye irritation.
  • GMD meibomian gland dysfunction
  • Blepharitis usually exists as a chronic condition, and chronic blepharitis can cause chronic meibomian gland dysfunction.
  • Ocular rosacea is as an inflammatory eye condition which causes persistent burning and a feeling of grittiness in the eyes, or inflamed/swollen eyelids with small-inflamed lesions.
  • the eyes become red or bloodshot, and sometimes eye lashes fall out.
  • the ocular symptoms of rosacea are exceedingly variable and include blepharitis.
  • Eyelid inflammations such as blepharitis, meibomitis, blepharoconjunctivitis, causes flaking of the skin on eyelids, crusting at eyelid margins, crusting of eyelashes, flaking of eye lashes, eye itching, eye irritation, burning of the eyes, redness of eyes/eyelids, swollen eyelids, gritty sensation in eye, eye discomfort, excessive tearing, gluing of the eyelashes, sticking of eyelids, infectious yellowish/greenish discharge from eyelids, and blurred vision.
  • Blepharitis may localize in the skin of the eyelids, causing a stye or a chalazion.
  • Topical treatments are often used as first-line treatments for eye infections and inflammations. Eye infections and inflammations can be treated within days to weeks depending on its severity. Eye infections are treated utilizing medications, while eyelid inflammations are treated utilizing a combination of eyelid scrubs and medications.
  • medications are applied to the eyelid margins and eyelashes by use of cotton swabs/buds which are soaked or moistened in the solution of medication to rub along the eyelid margins, for at least three to four times a day.
  • the cotton swabs/buds are used for removing the scaling and flaking around eye lashes, excess sebum production, oily scaly eye discharge, and crust and debris accumulated on and around the eyelashes and eyelid margins.
  • the present invention discloses a topical drug delivery system useful in treatment of infections and inflammations on body surfaces including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes of humans and animals.
  • the topical drug delivery system (1) of present invention comprises
  • liquid medication contained within the medical core member, and comprising at least one pharmaceutically active substance to be applied over an area of body surface to be treated;
  • the medical core member containing the liquid medication is held safely within the casing, in close contact with the applicator tip.
  • the medical core member stores, retains and transports the liquid medication within the casing to the applicator tip.
  • the applicator tip can be precisely dabbed over or rubbed across the body surface area to be treated, so as to apply the medication over the treatment area, without contamination through hands.
  • the topical drug delivery system of the present invention provides a finer, safer, hygienic and more convenient way of applying medications to body surface areas, which leads to effective and quick treatment of inflammations and infections.
  • Fig. 1 is a perspective view of a topical drug delivery system of the present invention.
  • Fig.2 is a cross-sectional view of a topical drug delivery system of the present invention.
  • Fig. 3 illustrates the technique of application of a liquid medication to a lower eyelid margin of a blepharitis-infected eye, through use of the topical drug delivery system of the present invention.
  • Fig. 4 illustrates the technique of application of a liquid medication to an infected body surface area, through use of the topical drug delivery system of the present invention.
  • Fig. 5 depicts a microscopic sketch of a healthy skin-hair/eyelash having circular cutical layers into which the medication gets delivered using the topical drug delivery system of the present invention.
  • Fig. 6 shows a microscopic sketch of an inflamed skin-hair/eyelash having ruffled cuticle layers with longitudinal grooves, and into which the medication gets delivered using the topical drug delivery system of the present invention.
  • Figure 1 refers to a perspective view of the topical drug delivery system (1) of present invention, which serves as an applicator for treatment of infections and inflammations on the body surfaces.
  • the topical drug delivery system comprises a hollow casing (2) having an application end (7) and a non-application end (6); a medical core member extending in an axial direction within the casing (2); and an applicator tip (3) protruding through the application end (7) of the casing.
  • the casing (2) is sealed at the non-application end (6) with a top cap (5) to safely contain the medical core member within the casing (2).
  • the medical core member contains a liquid medication comprising at least one pharmaceutically active substance to be applied over an infected/inflamed body surface area to be treated.
  • a removable end cap (4) is mounted over the application end (7) of the casing, in order to protect the applicator tip (3).
  • the casing (2) has a flange (2a) near its application end (7), and the removable end cap (4) correspondingly has an internal recessed portion (4a) to fit over the flange (2a) for secured mounting of the cap over the application end (7) of the casing.
  • different conventional mechanisms can be utilized for secured mounting of the top and end caps over the casing.
  • the removable end cap can be of any shape that securely fits over the application end of the casing.
  • the removable end cap may be provided with a clip, so as to hook the applicator to the user's pocket or belonging.
  • Fig. 2 is a cross-sectional view of the topical drug delivery system (I) of present invention, which shows the medical core member (8) impregnated with the liquid medication (9),extending axially within the hollow casing (2).
  • the medical core member (8) stores, retains as well as transports the liquid medication (9) within the casing. (2) to the applicator tip (3) that protrudes through the casing.
  • the medical core member (8) is in close contact with the applicator tip (3), and is safely held within the hollow casing (2) with the help of a screwed cap (5) fitted over the casing.
  • a spring member, a valve assembly and/or a dispensing mechanism may be fitted within the casing, to regulate the flow of liquid medication through the applicator tip.
  • the liquid medication used in present invention comprises at least one pharmaceutically active substance selected from but not limited to the group consisting of anti-infective and antiseptic agents.
  • concentration of liquid medication ranges from 0.001% to 10%.
  • Antiseptic agents are used for destroying fungi, bacteria, virus and other biological pathogens on the body surfaces.
  • the antiseptic agents used in the present invention include but are not limited to alcohols such as ethanol, propanol, isopropanol or mixtures thereof, chlorbutanol, benzalkonium chloride, chlorhexidine and derivative thereof, povidohe-iodine alone or in combination with methylated spirits or detergents, tincture iodine, cetrimide, benzethonium chloride, boric acid, hydrogen peroxide, sodium chloride, sodium hypochlorite, calcium hypochlorite, sodium bicarbonate, thymol, thiomerosal, thiomersalate, hexachlorophene, triclosan, sodium 3,5-dibromo-4- hydroxybenzenesulfonate, polyhexanide and mixtures thereof .
  • Anti-infective agents are used for removing the organisms causing infection from the body surfaces.
  • the anti-infective agents used in the present invention comprises antibacterials, antifungals and antiparasitics, which include but are not limited to penicillin, streptomycin, tetracyclines and derivative thereof, fluoroqinolones such as ciprofloxacin, ampicillin, amoxicillin, gentamicin, vancomycin, clindamycin, erythromycin, azithromycin, polymyxin, bacitracin, neomycin, polysporin, chloramphenicol , sulfaacetamide and its salts/derivatives, sulfur and mixtures thereof.
  • the medical core member is an absorbent material impregnated with the liquid medication, wherein the absorbent material is selected from but not limited to natural or synthetic absorbent fibers, such as cotton, sponge or foam.
  • the medical core is encased within a thin impervious material, while being exposed at both the axial ends, to prevent the oozing of the liquid medication from the delivery system.
  • the medical core member is a container containing the liquid medication, and the container is provided with a valve assembly and/or a dispensing mechanism, to control the dispensing of liquid medication from the container.
  • the applicator tip of the drug delivery system of the present invention is soft enough to be dabbed, moved or rubbed across the area of body surface to be treated, without causing pain, discomfort or damage to the patient.
  • the applicator tip is designed to have varied shape and width, and made of varied materials of construction, depending on the area of body surface to be treated for infection or inflammation, so as to conveniently deliver the medicated drug at the treatment area of the patient, without causing pain or damage.
  • the shape of the applicator tip can be circular, triangular, cylindrical or rectangular in nature.
  • the width of the applicator tip is in the range of 20 microns to 5000 microns.
  • the applicator tip of the drug delivery system of present invention is made of a material selected from a group consisting of natural fibers such as cotton fibers, synthetic fibers such as nylon fibers and polyester fibers, felt, porous sponge, synthetic foam such as polyurethane foam, polymers such as polyethylene, polypropylene and polytetrafluoroethylene, and other conventional materials used for making applicator tips.
  • The. hollow casing, medical container and the caps of the drug delivery system of the present invention are made from impervious material selected from but not limited to polymeric materials such as plastic, polyester, polyethylene and polypropylene, metal, glass and wood.
  • the height and width of the casing of applicator will differ depending on the location of body surface to be treated for infection or inflammation, and corresponding changes will be acquired for the width and heights of the container encased within the casing, as well as the caps of the applicator.
  • Fig. 3 illustrates the technique of application of a liquid medication to a lower eyelid margin (10) of a blepharitis-infected eye, through use of the applicator of the present invention. Accordingly, as the fine tip (3) is brought in contact and rubbed across the lower eyelid margin (10) and eyelashes (12), the liquid medication flows out from the fine tip (3) to be applied across them for cleansing of eyelids and eyelashes. In a similar manner, the liquid medication can be applied to the upper eyelid margin ( 1 1) and eyelashes (12) for cleansing of eyelids and eyelashes.
  • Figure 4 illustrates the technique of application of a liquid medication to an infected area (13) of a body surface (14) using the topical drug delivery system (1) of the present invention, which has an applicator tip (3) specifically designed for application of medication over the desired body surface (14) to be treated.
  • the application of anti- infective medication using the topical drug delivery system of present invention enables the anti-infective medication to reach deeper within the skin, beneath the skin surfaces and also in the hair follicles, thus killing the bacteria residing therein and providing an effective skin treatment.
  • FIG. 5 shows a microscopic sketch of a healthy skin-hair/eyelash having circular cutical layers (15) which serve as natural reservoirs for the liquid medication (16) applied using the topical drug delivery system of the present invention, thus offering a long lasting effect of the applied medication to provide an effective treatment.
  • FIG. 6 shows a microscopic sketch of an inflamed skin-hair/eyelash having ruffled cuticle layers with longitudinal grooves (17), and into which the liquid medication (16) gets delivered using the topical drug delivery system of the present invention.
  • the applicator tip When the drug delivery system of present invention is applied across the infected skin site or eyelid margins and eye lashes, the applicator tip enables the liquid medication (16) to be deposited into the ruffled cuticles and longitudinal grooves (17) of the skin-hair or eyelash, thus offering a long lasting effect of the applied medication, killing off the pathogenic fungi, yeast and bacteria, and providing an effective and facile treatment for the infections and inflammations on the body surfaces of humans and animals.
  • the topical drug delivery system of present invention is useful in treatment of infections and inflammations on body surfaces of humans and animals, and can uniformly apply medications on diverse application areas of body surface including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner.
  • the topical drug delivery system of present invention is designed & dimensioned to be held conveniently in the hand with a firm grip, for application of the medication precisely over the treatment area, and without contamination through hands.
  • the drug delivery system of present invention safely contains the desired medication, and applies the medication to the treatment area without any spillage.
  • the drug delivery system provides easy, hygienic and safe application of the medication to the body surfaces to be treated, in a convenient manner.
  • the novel topical drug delivery system of present invention is portable and can be easily carried in pockets and purses, without causing any inconvenience during travel.
  • the topical drug delivery system is cost effective, and is easily affordable by common people.
  • the topical drug delivery system of present invention provides a hygienic, safer, finer and convenient way for application of medication to the body surface areas for treatment of inflammations and infections on body surfaces of humans and animals, while preventing contamination through hands, and leading to facile and effective treatment.
  • the topical drug delivery system of present invention serves as an applicator in treatment of skin infections e.g. acne, eye infections, external ear infection, nostril infection, oral mucous membranes infections, and inflammations thereof which may be allergic, immunological or traumatic in nature.
  • skin infections e.g. acne, eye infections, external ear infection, nostril infection, oral mucous membranes infections, and inflammations thereof which may be allergic, immunological or traumatic in nature.
  • topical drug delivery system is particularly advantageous in treatment of eyelid inflammations such as blepharitis, meibomitis and blepharoconjunctivitis, as the applicator tip can precisely apply as well as rub the medication to the eyelid margins and eyelashes, providing a thorough cleansing of the eyelids and eyelashes, while reducing the risk of entering of the medication into the patient's eye, and thus avoiding eye irritation and discomfort'.
  • the applicator of present invention provides a finer, safer and convenient way for application of medication to the eyelids and eyelashes in effective dose concentrations for eye cleansing during treatment of eye inflammations, leading to effective and quick treatment of eye inflammations.
  • the advantages of using the topical drug delivery system of present invention in treatment of inflammations and infections related to eyes and eyelids such as blepharitis, meibomitis and blepharoconjunctivitis are stated as follows: i) The applicator offers a pen-like comfort with a firm grip and a fine tip for applying medication over the eyelids and eyelashes with better control and precision, and prevents the applied medication from entering into the patient's eye during the application, thus avoiding eye irritation & discomfort which makes the applicator safe for eye use.
  • the applicator provides thorough cleansing of eyelid margins and base of eyelashes due to its fine applicator tip which effectively reaches between the eyelashes; and applies the medication easily and uniformly over the eyelid margins and in between the eyelashes, while preventing the medication from entering into the eye.
  • the applicator contains measured quantities of medication already within it, to be dispensed for each application to the eyelids, thus making the applicator easy to be
  • the applicator applies the medication with greater ease and greater efficiency, while minimizing the risk of eye injury.
  • the applicator provides improved patient comfort due to its ease of handling and use, and ease of disposal with hygiene and safety.
  • the applicator eliminates the use of gloves and there is no possibility of contamination of the hands, during application of medication by the applicator. Also, the applicator is superior in terms of portability and storage.
  • the applicator facilitates the treatment for inflammation and infection related to eyes and eyelids.
  • the pH of a cyst or an abscess or a septic focus at the root of the eyelashes or in the meibomian gland posterior to the eyelashes is known to be alkaline i.e around 8, the said solution pH being acidic, rightly neutralizes the pH at said sites of infection, and thus makes the environment hostile for the infection-causing germs that grow in such alkaline pH at these sites, consequently enabling the patient to get rid of the inflammation and infection related to eyes and eyelids, in a facile manner.
  • topical drug delivery system of present invention is advantageous over the prior art cotton swabs useful in treatment of inflammations and infections related to eyes and eyelids, such as blepharitis, blepharoconjunctivitis, meibomitis and ocular rosacea, while preventing styes, chalazion, trichiasis, eyelash loss, ectropion and entropion.
  • the topical drug delivery system of present invention serves as an applicator in treatment of infections and inflammations related to eyes, eyelids, skin, external ear, nose and mouth.
  • the topical drug delivery system thoroughly cleanses as well as uniformly applies the liquid medications on diverse body surface areas of humans and animals, including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner, leading to facile and effective treatment.
  • the topical drug delivery system of present invention can be used for applying liquid medication to cuts and wounds or to desired body surface areas prior to surgery, and can be used in dental surgery.

Abstract

The present invention discloses a topical drug delivery system useful in treatment of infections and inflammations on body surfaces of humans and animals.

Description

"TOPICAL DRUG DELIVERY SYSTEM"
TECHNICAL FIELD:
The present invention relates to a novel topical drug delivery system useful in treatment of infections and inflammations on body surfaces of humans and animals.
BACKGROUND OF THE INVENTION:
Infections and inflammations are very common in humans and animals. Infection is an invasion of viruses, bacteria, parasites and fungi in the body; whereas inflammation is the first response of body's immune system to infection, irritation or injury caused to the body surface. Infections and inflammations can occur on any part of the body surfaces such as skin, eyes, ears, nose and mouth.
Skin forms a major part of the body surface which is exposed, and hence is most likely to get infected. Skin infections are often the result of breaks in the integrity of the skin, which enables pathogens such as virus, bacteria, fungi and yeast to inoculate into the dermis to cause infection. Skin infections can also result from a cut, scrape, insect bite, burn or any other skin wound. Skin infections caused by bacteria include acne/pimples, erythrasma, impetigo, ecthyma, folliculitis, erysipelas and cellulites. Skin infection can result in skin inflammation, which is known as infective dermatitis. Moreover infections to ears, nose and mouth that can lead to inflammation are also a growing cause of concern for humans and animals.
Topical treatment of such infections and inflammations generally involve mild cleansing of the infected site, and gentle application of required medication over the infected skin site. However, during such topical treatments, there is a possibility of contamination through hands used for applying the medication to infected site, while the hands barely reaching the site of application in certain cases, due to which hygienic and uniform application of medications to the treatment areas on body surfaces, is not achieved, and the period of treatment is further delayed. Therefore, treatments of infections and inflammations are required to achieve uniform application of medication over the treatment area, while maintaining proper hygiene of hands which is usually obtained using disposable hand gloves.
Many of the viruses, bacteria, parasites and fungi, which invade the human body and cause infections, are also capable of attacking the surface or interior of the eye, leading to eye infections and inflammations.
Eyelid is an important part of the eye, and eyelid inflammations have become a cause of major concern for most of the people suffering from eye diseases. Blepharitis, meibomitis, blepharoconjunctivitis, ocular rosacea, styes and chalazion are some of the eye diseases causing eyelid inflammation, which results into eye irritation, eye itching, eye discharge, excessive tear production and eye discomfort.
Blepharitis is an inflammation of the eyelids, particularly at the margins of the eyelids, caused due to collection of oil, dandruff, mucin, bacteria, pollutants or eye makeup on and around the eyelids and eyelashes. In blepharitis, dandruff-like scales and particles are formed along the eyelid margins and base of eyelashes. Blepharitis is mainly classified into i) anterior blepharitis that affects the outer margin of the eyelids where the eyelashes are located; and ii) posterior blepharitis that affects the inner rim of eyelids where the meibomian glands are situated. Blepharitis can occur as staphylococcal blepharitis, seborrhoeic blepharitis, allergic blepharitis, ulcerative blepharitis and/or blepharitis caused due to skin cancers or systemic medical conditions. Severe blepharitis can be associated with conjunctivitis, known as blepharoconjunctivitis.
Meibomitis is an inflammation of the meibomian glands located in the eyelids, and is very closely related to blepharitis. Meibomitis is also known as meibomian gland dysfunction (MGD), wherein the meibomian gland openings on the eyelid margins become blocked with inspicated meibomian secretions, and the oil secreted by the meibomian glands is thicker and has a milky appearance, rather than a clear oil that prevents tear evaporation, thus leading to eye irritation. Blepharitis usually exists as a chronic condition, and chronic blepharitis can cause chronic meibomian gland dysfunction.
Ocular rosacea is as an inflammatory eye condition which causes persistent burning and a feeling of grittiness in the eyes, or inflamed/swollen eyelids with small-inflamed lesions. In ocular rosacea, the eyes become red or bloodshot, and sometimes eye lashes fall out. The ocular symptoms of rosacea are exceedingly variable and include blepharitis.
Eyelid inflammations such as blepharitis, meibomitis, blepharoconjunctivitis, causes flaking of the skin on eyelids, crusting at eyelid margins, crusting of eyelashes, flaking of eye lashes, eye itching, eye irritation, burning of the eyes, redness of eyes/eyelids, swollen eyelids, gritty sensation in eye, eye discomfort, excessive tearing, gluing of the eyelashes, sticking of eyelids, infectious yellowish/greenish discharge from eyelids, and blurred vision. Blepharitis may localize in the skin of the eyelids, causing a stye or a chalazion. It may even lead to trichiasis, eyelash loss, ectropion and entropion. Some people may develop allergy to the scales or surrounding bacteria near the eyelid margins and eyelashes, leading to more serious complication with inflammation of other eye tissues such as the cornea, and may even lead to loss of vision.
Eye inflammations as well as eye infections, need to be controlled with good eye hygiene. Long-term eye care helps to ease the symptoms of eye infections and inflammations, and prevent it from recurring.
Topical treatments are often used as first-line treatments for eye infections and inflammations. Eye infections and inflammations can be treated within days to weeks depending on its severity. Eye infections are treated utilizing medications, while eyelid inflammations are treated utilizing a combination of eyelid scrubs and medications.
In topical treatment of eyelid inflammations such as blepharitis, meibomitis and blepharoconjunctivitis, medications are applied to the eyelid margins and eyelashes by use of cotton swabs/buds which are soaked or moistened in the solution of medication to rub along the eyelid margins, for at least three to four times a day. The cotton swabs/buds are used for removing the scaling and flaking around eye lashes, excess sebum production, oily scaly eye discharge, and crust and debris accumulated on and around the eyelashes and eyelid margins.
However, the use of cotton swabs/buds, for cleansing eyelid margins and eyelashes during treatment of eyelid inflammations seems to be improper due to the following reasons: i) The large and bulky tip of the cotton swab/bud is not suitable for applying the medication particularly and precisely over the eyelid margins and between the eye lashes, due to which thorough cleansing of eyelid margins and eyelashes is not achieved. ii) Excessive amount of medication gets soaked into the large and bulky tip of the new cotton swab/bud, each time before application of the medication to the eyelid, which leads to wastage of medication during cleansing of eyelids and eyelashes. Due to application of medication through such cotton swabs/buds soaked with excessive medication, some amount of medication is bound to enter into the patient's eye during cleansing of eyelids and eyelashes, leading to eye irritation & discomfort, which makes the cotton swab/bud unsafe for eye use. iii) Fluctuating amounts of medication gets soaked into each new cotton swab/bud used for application of medication to the eyelid, which seems to be an improper way for cleansing of eyelids and eyelashes. iv) The cotton swab/bud does not provide a firm gripping with controlled movement of the bud over the eyelid margins and eyelashes for application of the medication, resulting in damaging of the surrounding eye tissues, and further failing to provide thorough cleansing of eyelids and eyelashes, which makes the cotton swab/bud unsafe for eye use. v) The handling, usage and disposal of several cotton swabs/buds, each time during the cleansing of eyelid margins and eyelashes, is quite tedious, inconvenient and unhygienic. vi) Patient comfort is not achieved, as the patient has to dip a new cotton swab/bud into the medication each time, before application of medication to the eyelid for cleansing. Also, the patient hesitates to apply the medication to the eyelids and eyelashes, in front of others. Moreover, containers/bottles of medications need to be purchased and carried by the patients in their bags or purses, while prone to spillage, during traveling to work places and outdoor places, which is quite inconvenient for the patients.
Thus,from the aforementioned problems observed during treatment of eyelid inflammations, it is clear that there is a need for applicator for treatment of eyelid inflammations that provide thorough cleansing of eyelids and eyelashes, along with the application of medications in a safe and controlled manner.
Also, there exist a need for an applicator which provides hygienic and uniform application of medications to the affected areas of body surfaces in treatment of infections and inflammations, as treatment of infections and inflammations need to be controlled with good hygiene to provide effective and fast results of topical treatments.
There exists several applicators in prior art for individual treatments of body surfaces such as skin, eyes, ears, nose and mouth. However, the present inventors have designed a topical drug delivery system useful in treatment of infections and inflammations on body surfaces of humans and animals, which can apply medications on diverse application areas of body surface including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner.
SUMMARY OF THE INVENTION:
The present invention discloses a topical drug delivery system useful in treatment of infections and inflammations on body surfaces including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes of humans and animals. The topical drug delivery system (1) of present invention, comprises
- a hollow casing (2) having an application end (7) and a non-application end(6) ;
- a medical core member (8) extending in an axial direction within thecasing (2) ;
- a liquid medication contained within the medical core member, and comprising at least one pharmaceutically active substance to be applied over an area of body surface to be treated;
- an applicator tip (3) protruding through the application end (7) of the casing;
- a removable end cap (4) to be fitted over the applicator tip (3) for protecting the tip; • and
- a top cap (5) tightly fitted over the non-application end (6) of the casing, to safely contain the medical core member within the casing.
In the present invention, the medical core member containing the liquid medication, is held safely within the casing, in close contact with the applicator tip. The medical core member stores, retains and transports the liquid medication within the casing to the applicator tip. When the applicator is in use, the applicator tip can be precisely dabbed over or rubbed across the body surface area to be treated, so as to apply the medication over the treatment area, without contamination through hands.
The topical drug delivery system of the present invention, provides a finer, safer, hygienic and more convenient way of applying medications to body surface areas, which leads to effective and quick treatment of inflammations and infections.
BRIEF DESCRIPTION OF THE DRAWINGS:
In the accompanying drawings:
Fig. 1 is a perspective view of a topical drug delivery system of the present invention. Fig.2 is a cross-sectional view of a topical drug delivery system of the present invention. Fig. 3 illustrates the technique of application of a liquid medication to a lower eyelid margin of a blepharitis-infected eye, through use of the topical drug delivery system of the present invention.
Fig. 4 illustrates the technique of application of a liquid medication to an infected body surface area, through use of the topical drug delivery system of the present invention.
Fig. 5 depicts a microscopic sketch of a healthy skin-hair/eyelash having circular cutical layers into which the medication gets delivered using the topical drug delivery system of the present invention.
Fig. 6 shows a microscopic sketch of an inflamed skin-hair/eyelash having ruffled cuticle layers with longitudinal grooves, and into which the medication gets delivered using the topical drug delivery system of the present invention.
DETAILED DESCRIPTION:
The present invention will now be described with reference to the accompanying drawings.
Figure 1 refers to a perspective view of the topical drug delivery system (1) of present invention, which serves as an applicator for treatment of infections and inflammations on the body surfaces. The topical drug delivery system comprises a hollow casing (2) having an application end (7) and a non-application end (6); a medical core member extending in an axial direction within the casing (2); and an applicator tip (3) protruding through the application end (7) of the casing. The casing (2) is sealed at the non-application end (6) with a top cap (5) to safely contain the medical core member within the casing (2). The medical core member contains a liquid medication comprising at least one pharmaceutically active substance to be applied over an infected/inflamed body surface area to be treated. A removable end cap (4) is mounted over the application end (7) of the casing, in order to protect the applicator tip (3). The casing (2) has a flange (2a) near its application end (7), and the removable end cap (4) correspondingly has an internal recessed portion (4a) to fit over the flange (2a) for secured mounting of the cap over the application end (7) of the casing. However, different conventional mechanisms can be utilized for secured mounting of the top and end caps over the casing. The removable end cap can be of any shape that securely fits over the application end of the casing. Moreover, the removable end cap may be provided with a clip, so as to hook the applicator to the user's pocket or belonging.
Fig. 2 is a cross-sectional view of the topical drug delivery system (I) of present invention, which shows the medical core member (8) impregnated with the liquid medication (9),extending axially within the hollow casing (2). The medical core member (8) stores, retains as well as transports the liquid medication (9) within the casing. (2) to the applicator tip (3) that protrudes through the casing. The medical core member (8) is in close contact with the applicator tip (3), and is safely held within the hollow casing (2) with the help of a screwed cap (5) fitted over the casing. Although not shown in the figure, a spring member, a valve assembly and/or a dispensing mechanism, may be fitted within the casing, to regulate the flow of liquid medication through the applicator tip.
The liquid medication used in present invention, comprises at least one pharmaceutically active substance selected from but not limited to the group consisting of anti-infective and antiseptic agents. The concentration of liquid medication ranges from 0.001% to 10%.
Antiseptic agents are used for destroying fungi, bacteria, virus and other biological pathogens on the body surfaces. The antiseptic agents used in the present invention include but are not limited to alcohols such as ethanol, propanol, isopropanol or mixtures thereof, chlorbutanol, benzalkonium chloride, chlorhexidine and derivative thereof, povidohe-iodine alone or in combination with methylated spirits or detergents, tincture iodine, cetrimide, benzethonium chloride, boric acid, hydrogen peroxide, sodium chloride, sodium hypochlorite, calcium hypochlorite, sodium bicarbonate, thymol, thiomerosal, thiomersalate, hexachlorophene, triclosan, sodium 3,5-dibromo-4- hydroxybenzenesulfonate, polyhexanide and mixtures thereof . Anti-infective agents are used for removing the organisms causing infection from the body surfaces. The anti-infective agents used in the present invention comprises antibacterials, antifungals and antiparasitics, which include but are not limited to penicillin, streptomycin, tetracyclines and derivative thereof, fluoroqinolones such as ciprofloxacin, ampicillin, amoxicillin, gentamicin, vancomycin, clindamycin, erythromycin, azithromycin, polymyxin, bacitracin, neomycin, polysporin, chloramphenicol , sulfaacetamide and its salts/derivatives, sulfur and mixtures thereof.
In one aspect of invention, the medical core member is an absorbent material impregnated with the liquid medication, wherein the absorbent material is selected from but not limited to natural or synthetic absorbent fibers, such as cotton, sponge or foam. Moreover, the medical core is encased within a thin impervious material, while being exposed at both the axial ends, to prevent the oozing of the liquid medication from the delivery system.
In another aspect of invention, the medical core member is a container containing the liquid medication, and the container is provided with a valve assembly and/or a dispensing mechanism, to control the dispensing of liquid medication from the container.
The applicator tip of the drug delivery system of the present invention, is soft enough to be dabbed, moved or rubbed across the area of body surface to be treated, without causing pain, discomfort or damage to the patient. The applicator tip is designed to have varied shape and width, and made of varied materials of construction, depending on the area of body surface to be treated for infection or inflammation, so as to conveniently deliver the medicated drug at the treatment area of the patient, without causing pain or damage. The shape of the applicator tip can be circular, triangular, cylindrical or rectangular in nature. The width of the applicator tip is in the range of 20 microns to 5000 microns.
The applicator tip of the drug delivery system of present invention, is made of a material selected from a group consisting of natural fibers such as cotton fibers, synthetic fibers such as nylon fibers and polyester fibers, felt, porous sponge, synthetic foam such as polyurethane foam, polymers such as polyethylene, polypropylene and polytetrafluoroethylene, and other conventional materials used for making applicator tips. The. hollow casing, medical container and the caps of the drug delivery system of the present invention, are made from impervious material selected from but not limited to polymeric materials such as plastic, polyester, polyethylene and polypropylene, metal, glass and wood. Moreover, the height and width of the casing of applicator will differ depending on the location of body surface to be treated for infection or inflammation, and corresponding changes will be acquired for the width and heights of the container encased within the casing, as well as the caps of the applicator.
Fig. 3 illustrates the technique of application of a liquid medication to a lower eyelid margin (10) of a blepharitis-infected eye, through use of the applicator of the present invention. Accordingly, as the fine tip (3) is brought in contact and rubbed across the lower eyelid margin (10) and eyelashes (12), the liquid medication flows out from the fine tip (3) to be applied across them for cleansing of eyelids and eyelashes. In a similar manner, the liquid medication can be applied to the upper eyelid margin ( 1 1) and eyelashes (12) for cleansing of eyelids and eyelashes.
Most of the anti-infective medications show poor permeability into skin, and hence bacteria residing deeper in the skin or beneath the skin surface and in the hair follicles, often remain unaffected by the conventional methods, further worsening the skin condition.
Figure 4 illustrates the technique of application of a liquid medication to an infected area (13) of a body surface (14) using the topical drug delivery system (1) of the present invention, which has an applicator tip (3) specifically designed for application of medication over the desired body surface (14) to be treated. The application of anti- infective medication using the topical drug delivery system of present invention, enables the anti-infective medication to reach deeper within the skin, beneath the skin surfaces and also in the hair follicles, thus killing the bacteria residing therein and providing an effective skin treatment.
FIG. 5 shows a microscopic sketch of a healthy skin-hair/eyelash having circular cutical layers (15) which serve as natural reservoirs for the liquid medication (16) applied using the topical drug delivery system of the present invention, thus offering a long lasting effect of the applied medication to provide an effective treatment.
During infections and inflammations of skin and eyes, skin hair and eyelashes exhibit ruffled cuticle layers with longitudinal grooves, within which pathogenic fungi, yeast and bacteria reside that further worsen the skin/eye condition. FIG. 6 shows a microscopic sketch of an inflamed skin-hair/eyelash having ruffled cuticle layers with longitudinal grooves (17), and into which the liquid medication (16) gets delivered using the topical drug delivery system of the present invention. When the drug delivery system of present invention is applied across the infected skin site or eyelid margins and eye lashes, the applicator tip enables the liquid medication (16) to be deposited into the ruffled cuticles and longitudinal grooves (17) of the skin-hair or eyelash, thus offering a long lasting effect of the applied medication, killing off the pathogenic fungi, yeast and bacteria, and providing an effective and facile treatment for the infections and inflammations on the body surfaces of humans and animals.
The topical drug delivery system of present invention is useful in treatment of infections and inflammations on body surfaces of humans and animals, and can uniformly apply medications on diverse application areas of body surface including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner.
The topical drug delivery system of present invention is designed & dimensioned to be held conveniently in the hand with a firm grip, for application of the medication precisely over the treatment area, and without contamination through hands. The drug delivery system of present invention safely contains the desired medication, and applies the medication to the treatment area without any spillage. As a result, the drug delivery system provides easy, hygienic and safe application of the medication to the body surfaces to be treated, in a convenient manner. The novel topical drug delivery system of present invention is portable and can be easily carried in pockets and purses, without causing any inconvenience during travel. The topical drug delivery system is cost effective, and is easily affordable by common people.
As a result, the topical drug delivery system of present invention provides a hygienic, safer, finer and convenient way for application of medication to the body surface areas for treatment of inflammations and infections on body surfaces of humans and animals, while preventing contamination through hands, and leading to facile and effective treatment.
The topical drug delivery system of present invention serves as an applicator in treatment of skin infections e.g. acne, eye infections, external ear infection, nostril infection, oral mucous membranes infections, and inflammations thereof which may be allergic, immunological or traumatic in nature.
The use of topical drug delivery system is particularly advantageous in treatment of eyelid inflammations such as blepharitis, meibomitis and blepharoconjunctivitis, as the applicator tip can precisely apply as well as rub the medication to the eyelid margins and eyelashes, providing a thorough cleansing of the eyelids and eyelashes, while reducing the risk of entering of the medication into the patient's eye, and thus avoiding eye irritation and discomfort'. Thus, the applicator of present invention provides a finer, safer and convenient way for application of medication to the eyelids and eyelashes in effective dose concentrations for eye cleansing during treatment of eye inflammations, leading to effective and quick treatment of eye inflammations.
The advantages of using the topical drug delivery system of present invention in treatment of inflammations and infections related to eyes and eyelids such as blepharitis, meibomitis and blepharoconjunctivitis, are stated as follows: i) The applicator offers a pen-like comfort with a firm grip and a fine tip for applying medication over the eyelids and eyelashes with better control and precision, and prevents the applied medication from entering into the patient's eye during the application, thus avoiding eye irritation & discomfort which makes the applicator safe for eye use. ii) The applicator provides thorough cleansing of eyelid margins and base of eyelashes due to its fine applicator tip which effectively reaches between the eyelashes; and applies the medication easily and uniformly over the eyelid margins and in between the eyelashes, while preventing the medication from entering into the eye. iii) The applicator contains measured quantities of medication already within it, to be dispensed for each application to the eyelids, thus making the applicator easy to be
- used by the patient during cleansing of eyelids and eyelashes. iv) The applicator applies the medication with greater ease and greater efficiency, while minimizing the risk of eye injury." v) The applicator provides improved patient comfort due to its ease of handling and use, and ease of disposal with hygiene and safety. The applicator eliminates the use of gloves and there is no possibility of contamination of the hands, during application of medication by the applicator. Also, the applicator is superior in terms of portability and storage. vi) The applicator facilitates the treatment for inflammation and infection related to eyes and eyelids. For example: When a liquid medication of 5% povidone iodine solution which is known to have a pH of 5.4, is brushed across the eyelashes of the infected eye, using the topical drug delivery system of the present invention, said solution rightly reaches at the root of the eyelashes or in the meibomian gland posterior to the eyelashes, which are considered to be the main sites of infection. And, since the pH of a cyst or an abscess or a septic focus at the root of the eyelashes or in the meibomian gland posterior to the eyelashes, is known to be alkaline i.e around 8, the said solution pH being acidic, rightly neutralizes the pH at said sites of infection, and thus makes the environment hostile for the infection-causing germs that grow in such alkaline pH at these sites, consequently enabling the patient to get rid of the inflammation and infection related to eyes and eyelids, in a facile manner.
Thus, the use of topical drug delivery system of present invention is advantageous over the prior art cotton swabs useful in treatment of inflammations and infections related to eyes and eyelids, such as blepharitis, blepharoconjunctivitis, meibomitis and ocular rosacea, while preventing styes, chalazion, trichiasis, eyelash loss, ectropion and entropion.
The topical drug delivery system of present invention, serves as an applicator in treatment of infections and inflammations related to eyes, eyelids, skin, external ear, nose and mouth. The topical drug delivery system thoroughly cleanses as well as uniformly applies the liquid medications on diverse body surface areas of humans and animals, including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner, leading to facile and effective treatment. The topical drug delivery system of present invention, can be used for applying liquid medication to cuts and wounds or to desired body surface areas prior to surgery, and can be used in dental surgery.

Claims

We claim:
1. A topical drug delivery system (1) useful in treatment of infections and inflammations on body surfaces of humans and animals, comprising
a hollow casing (2) having an application end (7) and a non-application end (6) ; a medical core member (8) extending in an axial direction within the casing (2) ; a liquid medication contained within the medical core member;
an applicator tip (3) protruding through the application end (7) of the casing; a removable end cap (4) to be fitted over the applicator tip (3) for protecting the tip; and
a top cap (5) tightly fitted over the non-application end (6) of the casing, to safely contain the medical core member within the casing.
2. The topical drug delivery system as claimed in claim 1, wherein the medical core member (8) containing the liquid medication, is held safely within the casing (2), in close contact with the applicator tip (3).
3. The topical drug delivery system as claimed in claim 1, wherein the medical core member (8) comprises an absorbent material impregnated with the liquid medication, or a container containing a liquid medication.
4. The topical drug delivery system as claimed in claim 1, wherein the liquid medication comprises at least one pharmaceutically active substance to be applied over an infected /inflamed area of body surface to be treated.
5. The topical drug delivery system as claimed in claim 4, wherein the pharmaceutically active substance is selected from a group consisting of anti-infective and antiseptic agents.
6. The topical drug delivery system as claimed in claim 3, wherein the absorbent material comprises of natural absorbent fibers and/or synthetic absorbent fibers.
7. The topical drug delivery system as claimed in claim 6, wherein the absorbent material is selected from a group consisting of cotton, sponge and foam.
8. The topical drug delivery system as claimed in claim 3, wherein the absorbent material is encased within a thin impervious material.
9. The topical drug delivery system as claimed in claim 1 and 3, wherein the hollow casing, the end cap, the top cap and the container, are made from impervious material.
10. The topical drug delivery system as claimed in claim 8 and 9, wherein the impervious material is selected from a group consisting of polymeric materials such as plastic, polyester, polyethylene or polypropylene, metal, glass and wood.
1 1. The topical drug delivery system as claimed in claim 1, wherein the applicator tip (3) has a width ranging from 20 microns to 5000 microns.
12. The topical drug delivery system as claimed in claim 1 1, wherein the applicator tip, is made of a material selected from a group consisting of natural fibers including cotton fibers, synthetic fibers including nylon fibers and polyester fibers, felt, porous sponge, synthetic foam including polyurethane foam, and polymers including polyethylene, polypropylene and polytetrafluoroethylene.
13. Thetopical drug delivery system as claimed in claim 1, further comprises a spring member, a valve assembly, a dispenser or a combination thereof, for regulating the flow of liquid medication through the applicator tip.
14. The topical drug delivery system as claimed in claim 1, is portable.
15. The topical drug delivery system as claimed in claim 1, wherein the removable end cap has a clip to hook the applicator to the user's pocket or belonging.
16. The topical drug delivery system as claimed in claim 1 , is useful in treatment of infections and inflammations related to eyes , eyelids, skin, external ear, nose and mouth.
17. The topical drug delivery system as claimed in claim 1, wherein the liquid medication is uniformly applied to diverse body surface areas including surfaces of eyes, eyelids, eyelid margins, skin surface, external ear surface, nostrils and oral mucous membranes, in a safe, controlled and hygienic manner.
18. The topical drug delivery system as claimed in claim 16, is preferably useful in treatment of inflammations and infections related to eyes and eyelids, such as blepharitis, blepharoconjunctivitis, meibomitis and ocular rosacea.
PCT/IN2013/000530 2012-09-03 2013-08-30 "topical drug delivery system" WO2014045300A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2557/MUM/2012 2012-09-03
IN2557MU2012 2012-09-03

Publications (2)

Publication Number Publication Date
WO2014045300A2 true WO2014045300A2 (en) 2014-03-27
WO2014045300A3 WO2014045300A3 (en) 2014-05-22

Family

ID=50342035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000530 WO2014045300A2 (en) 2012-09-03 2013-08-30 "topical drug delivery system"

Country Status (1)

Country Link
WO (1) WO2014045300A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031137A1 (en) 2015-08-19 2017-02-23 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
IT202100028352A1 (en) * 2021-11-08 2023-05-08 Iromed Group S R L INSTRUMENT FOR REMOVING A DEPOSIT FROM AN EYE AND RELATED DISPOSABLE KIT

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578055A (en) * 1979-07-25 1986-03-25 Fischer Dan E Controlled diffusion medicament applicator
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US6487447B1 (en) * 2000-10-17 2002-11-26 Ultra-Sonic Technologies, L.L.C. Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation
US20070203458A1 (en) * 2004-09-24 2007-08-30 Sanofi-Aventis Deutschland Gmbh Cap For Drug Delivery Devices
US20080275468A1 (en) * 2007-04-27 2008-11-06 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
US20110319865A1 (en) * 2010-06-29 2011-12-29 Genesis Biosystems, Inc. Microneedle roller (mnr) infusion system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578055A (en) * 1979-07-25 1986-03-25 Fischer Dan E Controlled diffusion medicament applicator
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US6487447B1 (en) * 2000-10-17 2002-11-26 Ultra-Sonic Technologies, L.L.C. Method and apparatus for in-vivo transdermal and/or intradermal delivery of drugs by sonoporation
US20070203458A1 (en) * 2004-09-24 2007-08-30 Sanofi-Aventis Deutschland Gmbh Cap For Drug Delivery Devices
US20080275468A1 (en) * 2007-04-27 2008-11-06 Echo Therapeutics, Inc. Skin permeation device for analyte sensing or transdermal drug delivery
US20110319865A1 (en) * 2010-06-29 2011-12-29 Genesis Biosystems, Inc. Microneedle roller (mnr) infusion system

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017031137A1 (en) 2015-08-19 2017-02-23 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
IT202100028352A1 (en) * 2021-11-08 2023-05-08 Iromed Group S R L INSTRUMENT FOR REMOVING A DEPOSIT FROM AN EYE AND RELATED DISPOSABLE KIT

Also Published As

Publication number Publication date
WO2014045300A3 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
US8133193B2 (en) Method for treatment of skin diseases and the like
JP6182643B2 (en) Methods and kits for eye treatment
JP5041643B2 (en) Anti-infectious composition for treating damaged tissue such as herpes simplex
US6254294B1 (en) Pharmaceutical kit
US3948265A (en) Medicated applicator
KR102612453B1 (en) Anti-infective methods, compositions, and devices
ES2666174T3 (en) Cleaning compositions and methods for using them
US20110307039A1 (en) Device, method and system for treatment of sinusitis
US6688497B2 (en) Apparatus and method for tissue rinse
JP2014516690A (en) Container closure system containing antibacterial additives
US20150320594A1 (en) Systems, Methods, and Kits for Cleansing an Ocular Region
US20160193079A1 (en) Approach to administering ocular medication
US20170100574A1 (en) Apparatus configured for accurate up-loading of a single dose onto a delivery applicator
WO2012085139A1 (en) Otic composition for companion animals
WO2014045300A2 (en) "topical drug delivery system"
KR200433930Y1 (en) The spittle of bee toxin
KR20110036919A (en) Electrostatically charged nasal application multipurpose product and method
CN204158115U (en) A kind of sleep-helping healthcare pillow inserted sheet containing herbal medicine essential oil
US10888590B2 (en) Medicated propolis oil composition
US20050009790A1 (en) Ear and wound treatment
JP2006116071A (en) Ophthalmic medicine administration equipment
CN109966311A (en) A kind of eyelid thimerosal, pasteurization towelette and pasteurization towelette packaging bag
BR112021008552A2 (en) compositions and methods for treating transient biofilms
ES2777531T3 (en) Systems, methods and kits for cleaning an eye region
RU76803U1 (en) UNIVERSAL ACTIVATING ADJUSTMENT "CLEVLINK" TO PERFORMANCE DISPOSERS, APPLICATORS OF PACKAGING OF DEODORIZING, ANTI-PERSPIRATING, BIOLOGICALLY ACTIVE, MEDICINAL

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13839750

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13839750

Country of ref document: EP

Kind code of ref document: A2